In the BioHarmony Drug Report Database

"Preview" Icon

Baricitinib

Olumiant (baricitinib) is a small molecule pharmaceutical. Baricitinib was first approved as Olumiant on 2017-02-13. It is used to treat rheumatoid arthritis in the USA. It has been approved in Europe to treat rheumatoid arthritis. The pharmaceutical is active against tyrosine-protein kinase JAK2 and tyrosine-protein kinase JAK1. In addition, it is known to target cyclin-G-associated kinase, non-receptor tyrosine-protein kinase TYK2, BMP-2-inducible protein kinase, AP2-associated protein kinase 1, and tyrosine-protein kinase JAK3. Olumiant’s patents are valid until 2030-06-08 (FDA).

 

Trade Name

 

Olumiant
 

Common Name

 

baricitinib
 

ChEMBL ID

 

CHEMBL2105759
 

Indication

 

rheumatoid arthritis
 

Drug Class

 

Tyrosine kinase inhibitors: janus kinase inhibitors

Image (chem structure or protein)

Baricitinib structure rendering